Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-1.48%
+0.04%
+1.28%
+11.26%
Most Trending
-1.48%
+0.04%
+1.28%
+11.26%
$BA Vertical Research upgraded Boeing to Buy, citing improvements in supply chain efficiency and a stronger outlook. The stock edged up slightly to $230.95, reflecting steady investor confidence in Boeing’s ability to navigate industry challenges while positioning itself for growth in commercial aviation.
$DUOL Canaccord Genuity initiated coverage on Duolingo with a Buy rating and a $68 price target. The stock, trading at $271.28, saw minimal movement today but stands to benefit from analyst optimism around user growth and the company’s expanding educational platform, signaling potential near-term gains.
$ETNB H.C. Wainwright reinforced their Buy rating on 89bio, maintaining investor focus despite a modest pullback to $8.57. Analysts highlight the company’s innovative pipeline and strategic positioning in biotech as reasons to watch for momentum in coming sessions.
$HL Hecla Mining caught attention with a notable upgrade, surging 12.2% to $10.12. Zacks highlights strong earnings trends and the company’s ability to capitalize on volatile commodity markets as factors driving renewed investor interest, positioning HL as a standout performer.
$IFF International Flavors & Fragrances received multiple upgrades, driven by Wolfe Research’s confidence and potential asset sales. Trading at $66.21, the stock’s steady gains reflect market optimism over strategic initiatives and expansion prospects within the consumer staples sector.
$IOVA H.C. Wainwright maintained a Buy rating on Iovance following Health Canada authorization news. Despite a decline to $2.38, the company’s regulatory progress and promising oncology pipeline keep it in analysts’ favor for near-term upside potential.
$KURA LifeSci Capital reaffirmed a Buy rating on Kura Oncology, with shares slipping slightly to $8.14. Analysts remain positive on the company’s clinical development progress, signaling confidence in its longer-term growth prospects.
$NVDA Nvidia saw a price target cut from Citi but retained a Buy rating, with shares gaining 0.77% to $168.31. The company remains a key player in AI infrastructure, and despite short-term competitive pressures, analysts continue to see Nvidia as a core growth story in tech.
$OGE Energy received an upgrade based on its strong infrastructure projects, renewable expansion, and steady dividends. Trading at $43.46, the stock reflects investor interest in stable, utility-based growth plays with reliable income potential.
$RBLX Roblox analysts maintained Buy ratings, with BofA raising the price target from $159 to $171. Shares rose to $128.47, fueled by positive developments in developer payouts and growth in the gaming ecosystem, underlining Roblox’s innovation-driven upside.
$RLAY Guggenheim maintained a Buy rating on Relay Therapeutics, with shares at $4.06. Analysts point to the company’s early-stage clinical developments and strategic partnerships as reasons to watch for potential inflection points in value.
$SCHW Charles Schwab remained a Buy on Truist Securities recommendation, climbing 1.52% to $93.45. Analysts highlight its oversold conditions and strong fundamentals as reasons for potential near-term upside in the financial sector.
$SNY Sanofi received an upgrade at Morgan Stanley, driven by potential in amlitelimab versus Dupixent. Shares rose to $46.80, reflecting optimism over product development and strategic positioning in the biotech and pharmaceutical sector.
$STNG Scorpio Tankers surged 10.63% to $58.62 following a BofA upgrade to Buy. The shipping and transport stock is benefiting from strong earnings visibility and a favorable market for tanker demand, positioning it as a high-momentum candidate.
$TECK Teck Resources was raised by Deutsche Bank on its strategic value and self-help initiatives. Shares climbed 2.3% to $35.11, reflecting market confidence in its ability to navigate commodity cycles and capitalize on operational efficiencies.
$VEEV Veeva Systems received multiple upgrades, moving from Neutral to Overweight at JP Morgan and from Equal-Weight to Overweight at Morgan Stanley. Shares rose 3.61% to $282.78, as analysts cite strong SaaS growth, CRM adoption in life sciences, and market leadership as catalysts for continued upside.
Join StocksRunner.com for daily market updates, expert analyses, and actionable insights.
Signup now for FREE and stay ahead of the market curve!
Find out what 10,000+ subscribers already know.
Real-time insights for informed decisions.
Limited slots available, SignUp Now!
Please note that the content above should not be considered as investment advice or marketing. It does not take into account the personal data and requirements of any individual. This content is not a substitute for the reader's own judgment and should not be considered as advice or a recommendation for buying or selling any securities or financial products.
Get all the pieces of the puzzle on important data activity before the major news sources break the story and find out what happening right now and what could happen in the future
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Real-time stock market updates
Expert stock analysis
Investment strategies
Top stock recommendations
Trading signals and opportunities
Discover what is happening right now and piece together the key data activity before the major news outlets catch on. Stay ahead of the trends
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
The Score performance whether actual or indicated by historical tests of strategies, is no guarantee of future performance or success. The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained.
The results reflect performance of a strategy not historically offered to investors and does not represent returns that any investor actually attained. The Readiness Indicators, Sentiment Indicators and total score are calculated by the retroactive application of a model constructed on the basis of historical data and based on assumptions integral to the model which may or may not be testable and are subject to losses. Active trading is generally not appropriate for someone of limited resources, limited invesment or trading experience, or low-risk tolerance. Your capital may be at risk.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.